Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bone Marrow Transplantation-Pipeline Review, H1 2015

Bone Marrow Transplantation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bone Marrow Transplantation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bone Marrow Transplantation-Pipeline Review, H1 2015', provides an overview of the Bone Marrow Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bone Marrow Transplantation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Bone Marrow Transplantation Overview 8

Therapeutics Development 9

Pipeline Products for Bone Marrow Transplantation-Overview 9

Pipeline Products for Bone Marrow Transplantation-Comparative Analysis 10

Bone Marrow Transplantation-Therapeutics under Development by Companies 11

Bone Marrow Transplantation-Therapeutics under Investigation by Universities/Institutes 12

Bone Marrow Transplantation-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Bone Marrow Transplantation-Products under Development by Companies 16

Bone Marrow Transplantation-Products under Investigation by Universities/Institutes 17

Bone Marrow Transplantation-Companies Involved in Therapeutics Development 18

Anchor Therapeutics, Inc. 18

Boryung Pharmaceutical Co., Ltd. 19

Cantex Pharmaceuticals, Inc. 20

Cellerant Therapeutics, Inc. 21

Cleveland BioLabs, Inc. 22

Compugen Ltd. 23

Mesoblast Limited 24

Pluristem Therapeutics Inc. 25

Proteonomix, Inc. 26

Spectrum Pharmaceuticals, Inc. 27

Taiga Biotechnologies, Inc. 28

Wellstat Therapeutics Corporation 29

Bone Marrow Transplantation-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(filgrastim + plerixafor)-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ATI-2341-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

BR-05001-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CBLB-612-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Cell Therapy for Bone Marrow Transplantation-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

CGEN-15001-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

melphalan-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

MPC-CBE-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

PGX-100-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

PLX-RAD-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

PN-951-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Protein for Bone Marrow Transplantation-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

romyelocel-L-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules to Inhibit Perforin for Bone Marrow Transplantation-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Bone Marrow Transplantation-Recent Pipeline Updates 60

Bone Marrow Transplantation-Dormant Projects 70

Bone Marrow Transplantation-Discontinued Products 71

Bone Marrow Transplantation-Product Development Milestones 72

Featured News & Press Releases 72

Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 72

Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 73

Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 74

Oct 27, 2014: Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 74

Apr 23, 2014: Spectrum Pharmaceuticals' Pivotal Trial of Captisol-Enabled Melphalan Meets Primary Endpoint 75

May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 76

Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 77

May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 78

Feb 01, 2012: Ligand Presents Successful Phase II Results For Captisol-Enabled, Propylene Glycol-Free Melphalan At BMT Tandem Meetings 79

Jul 07, 2011: Mesoblast Receives FDA Clearance For Phase III Bone Marrow Transplant Trial 80

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

Number of Products under Development for Bone Marrow Transplantation, H1 2015 9

Number of Products under Development for Bone Marrow Transplantation-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Bone Marrow Transplantation-Pipeline by Anchor Therapeutics, Inc., H1 2015 18

Bone Marrow Transplantation-Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 19

Bone Marrow Transplantation-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 20

Bone Marrow Transplantation-Pipeline by Cellerant Therapeutics, Inc., H1 2015 21

Bone Marrow Transplantation-Pipeline by Cleveland BioLabs, Inc., H1 2015 22

Bone Marrow Transplantation-Pipeline by Compugen Ltd., H1 2015 23

Bone Marrow Transplantation-Pipeline by Mesoblast Limited, H1 2015 24

Bone Marrow Transplantation-Pipeline by Pluristem Therapeutics Inc., H1 2015 25

Bone Marrow Transplantation-Pipeline by Proteonomix, Inc., H1 2015 26

Bone Marrow Transplantation-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 27

Bone Marrow Transplantation-Pipeline by Taiga Biotechnologies, Inc., H1 2015 28

Bone Marrow Transplantation-Pipeline by Wellstat Therapeutics Corporation, H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Assessment by Combination Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Bone Marrow Transplantation Therapeutics-Recent Pipeline Updates, H1 2015 60

Bone Marrow Transplantation-Dormant Projects, H1 2015 70

Bone Marrow Transplantation-Discontinued Products, H1 2015 71

List of Figures

Number of Products under Development for Bone Marrow Transplantation, H1 2015 9

Number of Products under Development for Bone Marrow Transplantation-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anchor Therapeutics, Inc.

Boryung Pharmaceutical Co., Ltd.

Cantex Pharmaceuticals, Inc.

Cellerant Therapeutics, Inc.

Cleveland BioLabs, Inc.

Compugen Ltd.

Mesoblast Limited

Pluristem Therapeutics Inc.

Proteonomix, Inc.

Spectrum Pharmaceuticals, Inc.

Taiga Biotechnologies, Inc.

Wellstat Therapeutics Corporation

Bone Marrow Transplantation Therapeutic Products under Development, Key Players in Bone Marrow Transplantation Therapeutics, Bone Marrow Transplantation Pipeline Overview, Bone Marrow Transplantation Pipeline, Bone Marrow Transplantation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com